BioSpace News Archive

Curium, a world leader in nuclear medicine, and PIUR IMAGING announced today a strategic partnership to advance thyroid diagnostics in Germany.

Hummingbird Diagnostics GmbH today announced the presentation of groundbreaking research data at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in Boston.

CANbridge Pharmaceuticals, Inc. today announced that data from the preclinical evaluation of CAN201, a potential gene therapy for Fabry disease, will be presented at the at the European Society Gene & Cell Therapy (ESGCT) 30th Annual Congress, taking place from October 24-27 in Brussels, Belgium.

3T Biosciences (“3T”) today announced the appointment of Bryan Irving, Ph.D., as chief scientific officer (CSO). In this role, Dr. Irving will be responsible for the company’s scientific strategy and direction and will chair 3T’s Scientific Advisory Board.

Cerevance, a private, clinical-stage drug discovery and development company focused on developing precision novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced participation at the upcoming Wells Fargo 2023 Private Biotech Symposium, taking place virtually on November 1, 2023.

Larkspur Biosciences announced that data supporting development of a novel investigational therapy targeting Pin1 will be featured in a poster presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2023) on November 3 in San Diego, CA.

Fate Therapeutics, Inc. today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2023 at 5:00 PM ET to report its third quarter 2023.

Anavex Life Sciences Corp. today reported a new peer-reviewed publication in the journal Neurobiology of Aging, titled “Early treatment with an M1 and sigma-1 receptor agonist prevents cognitive decline in a transgenic rat model displaying Alzheimer-like amyloid pathology”, featuring the orally available small molecule ANAVEX®3-71 (AF710B).

Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced preclinical data supporting the safety and tolerability of the RaniPill® drug delivery platform following 60-day repeat administration.

Recce Pharmaceuticals Ltd today announced an Independent Safety Committee has approved the next cohort dosing at a faster infusion rate of 15 minutes of 3,000mg in a Phase I/II clinical trial evaluating its lead anti-infective candidate, RECCE® 327.